Trial Outcomes & Findings for Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study (NCT NCT05530356)

NCT ID: NCT05530356

Last Updated: 2026-08-24

Results Overview

Glomerular filtration rate measured by iohexol clearance

Recruitment status

COMPLETED

Target enrollment

57 participants

Primary outcome timeframe

One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

Results posted on

2026-08-24

Participant Flow

Most participants will be re-recruited from the parent Renal-HEIR study (COMIRB #16-1752), who consented to be contacted for future research. New participants will also be recruited via the Lifestyle Medicine 2 clinic at Children's Hospital Colorado, by email, phone, and during clinical visits.

Participant milestones

Participant milestones
Measure
Lean Control
Participants with BMI between 5th and 85th percentile, no T2D
Obese Control
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Type 2 Diabetes
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Overall Study
STARTED
9
15
33
Overall Study
COMPLETED
9
15
33
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Total
n=57 Participants
Total of all reporting groups
Age, Continuous
19 Years
STANDARD_DEVIATION 2 • n=1541 Participants
21 Years
STANDARD_DEVIATION 4 • n=1121 Participants
34 Years
STANDARD_DEVIATION 19 • n=2662 Participants
28 Years
STANDARD_DEVIATION 16 • n=113 Participants
Sex: Female, Male
Female
2 Participants
n=1541 Participants
5 Participants
n=1121 Participants
22 Participants
n=2662 Participants
29 Participants
n=113 Participants
Sex: Female, Male
Male
7 Participants
n=1541 Participants
10 Participants
n=1121 Participants
11 Participants
n=2662 Participants
28 Participants
n=113 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
0 Participants
n=2662 Participants
0 Participants
n=113 Participants
Race (NIH/OMB)
Asian
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
2 Participants
n=2662 Participants
2 Participants
n=113 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
0 Participants
n=2662 Participants
0 Participants
n=113 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
5 Participants
n=2662 Participants
5 Participants
n=113 Participants
Race (NIH/OMB)
White
9 Participants
n=1541 Participants
15 Participants
n=1121 Participants
25 Participants
n=2662 Participants
49 Participants
n=113 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
0 Participants
n=2662 Participants
0 Participants
n=113 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
1 Participants
n=2662 Participants
1 Participants
n=113 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=1541 Participants
11 Participants
n=1121 Participants
18 Participants
n=2662 Participants
31 Participants
n=113 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7 Participants
n=1541 Participants
4 Participants
n=1121 Participants
15 Participants
n=2662 Participants
26 Participants
n=113 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=1541 Participants
0 Participants
n=1121 Participants
0 Participants
n=2662 Participants
0 Participants
n=113 Participants
Glomerular filtration rate
135 mL/min/1.73m^2
STANDARD_DEVIATION 20 • n=1541 Participants
147 mL/min/1.73m^2
STANDARD_DEVIATION 30 • n=1121 Participants
149 mL/min/1.73m^2
STANDARD_DEVIATION 32 • n=2662 Participants
146 mL/min/1.73m^2
STANDARD_DEVIATION 29 • n=113 Participants

PRIMARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

Glomerular filtration rate measured by iohexol clearance

Outcome measures

Outcome measures
Measure
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Glomerular Filtration Rate
147 mL/min/1.73m^2
Standard Deviation 30
135 mL/min/1.73m^2
Standard Deviation 20
149 mL/min/1.73m^2
Standard Deviation 32

PRIMARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

Effective renal plasma flow measured by PAH clearance

Outcome measures

Outcome measures
Measure
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Effective Renal Plasma Flow (ERPF)
737 mL/min/1.73m^2
Standard Deviation 129
666 mL/min/1.73m^2
Standard Deviation 113
753 mL/min/1.73m^2
Standard Deviation 168

PRIMARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

BOLD-MRI uses the specific paramagnetic properties of deoxyhemoglobin to assess renal tissue oxygenation. Its outcome measure is the so-called R2\* value, which varies inversely with local oxygenation. This apparent relaxation rate R2\* (or decay rate, defined as 1/T2\* and expressed as per second) is measured voxel by voxel in each kidney by BOLD-MRI. The R2\* value of each voxel is influenced by microscopic inhomogeneities in the static magnetic field, largely due to the effect of deoxyhemoglobin. As such, the decay rate R2\* in a voxel will be enhanced when the local deoxyhemoglobin concentration is increased. Hence, assuming that blood pO2 is in equilibrium with tissue pO2, low R2\* values indicate high tissue oxygenation, while high R2\* values indicate low tissue oxygenation.

Outcome measures

Outcome measures
Measure
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Renal Oxygen Availability
17.9 1/s
Standard Deviation 1.1
18.9 1/s
Standard Deviation 1.6
18.8 1/s
Standard Deviation 1.8

PRIMARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

Arterial spin labeling (ASL) uses magnetically labeled arterial blood water as an endogenous tracer to assess renal perfusion. Its outcome measure is renal blood flow (RBF), expressed in mL/min/100 g of tissue. In ASL, inflowing arterial blood is magnetically tagged by inverting the longitudinal magnetization of water protons proximal to the imaging plane. After a defined post-labeling delay allowing labeled blood to flow into the tissue, a labeled image is acquired and subtracted from a control image obtained without labeling. The resulting difference signal, measured voxel by voxel in each kidney, is proportional to the labeled blood water delivered during the delay. As such, the difference signal in a voxel will be enhanced when local blood delivery is increased. Hence, after quantification using tissue and blood relaxation parameters, high perfusion values indicate high renal blood flow, while low perfusion values indicate reduced renal blood flow.

Outcome measures

Outcome measures
Measure
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Renal Perfusion
242.1 ml/min/100gm
Standard Deviation 48.8
193.9 ml/min/100gm
Standard Deviation 35.9
205.0 ml/min/100gm
Standard Deviation 41.0

PRIMARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

C-11 Acetate tracer uptake measured by PET Scan (K1)

Outcome measures

Outcome measures
Measure
Obese Control
n=21 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=10 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
C-11 Acetate Tracer Uptake
1.100 mL/min/mL
Standard Deviation 0.222
1.298 mL/min/mL
Standard Deviation 0.256

PRIMARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

Positron emission tomography (PET) with C-11 acetate is used to assess renal oxidative metabolism. Its outcome measure is the cortical clearance rate constant k2, expressed per minute (min\^-1). Following intravenous injection, C-11 acetate is taken up by renal tissue and converted to acetyl-CoA, which enters the tricarboxylic acid (TCA) cycle and is oxidized to C-11 CO2. The washout of C-11 activity from the tissue, modeled region by region in the renal cortex, reflects the rate of this oxidative process. The clearance rate constant k2, derived from kinetic modeling of the tissue time-activity curve, will be enhanced when oxidative metabolism and TCA cycle flux are increased. Hence, assuming tracer washout is in proportion to mitochondrial oxidation, high cortical k2 values indicate high renal oxidative metabolism, while low cortical k2 values indicate reduced renal oxidative metabolism.

Outcome measures

Outcome measures
Measure
Obese Control
n=21 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=10 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Renal Oxidative Metabolism
0.221 1/min
Standard Deviation 0.023
0.218 1/min
Standard Deviation 0.055

SECONDARY outcome

Timeframe: One-time measure collected at a single visit following screening; timing varied by participant, up to 7 months after screening

PWV between carotid and femoral artery

Outcome measures

Outcome measures
Measure
Obese Control
n=15 Participants
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Lean Control
n=9 Participants
Participants with BMI between 5th and 85th percentile, no T2D
Type 2 Diabetes
n=33 Participants
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
Pulse Wave Velocity
6.2 m/s
Standard Deviation 1.8
5.3 m/s
Standard Deviation 0.8
5.5 m/s
Standard Deviation 1.3

Adverse Events

Lean Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Obese Control

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Type 2 Diabetes

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Lean Control
n=9 participants at risk
Participants with BMI between 5th and 85th percentile, no T2D
Obese Control
n=15 participants at risk
BMI greater than or equal to 85th percentile for age/sex (or greater than or equal to 30 kg/m\^2 if adult), no diagnosis of T2D by ADA criteria
Type 2 Diabetes
n=33 participants at risk
BMI greater than or equal to 85th percentile, T2D diagnosed prior to 25 years of age per standard ADA T2D criteria. HbA1c \< 14% and no recent DKA or hyperosmolar hyperglycemia.
General disorders
Allergic reaction to Dextran
0.00%
0/9 • From enrollment until the end of study participation, an average of 1 month
6.7%
1/15 • From enrollment until the end of study participation, an average of 1 month
6.1%
2/33 • From enrollment until the end of study participation, an average of 1 month

Additional Information

Petter Bjornstad, MD

University of Washington; University of Colorado Anschutz Medical Campus

Phone: 206-616-3543

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place